References
- Ortega H, Llanos JP, Lafeuille MH, et al. Burden of disease associated with a COPD eosinophilic phenotype. Int J Chron Obstruct Pulmon Dis. 2018;13:2425–2433. doi:10.2147/COPD.S170995
- Higham A, Quinn AM, Cançado JED, et al. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res. 2019;20(1):49. doi:10.1186/s12931-019-1017-y
- Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC
- Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in central and Eastern Europe: the POPE Study. Eur Respir J. 2017;49(5):5. doi:10.1183/13993003.01446-2016
- Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27.
- Roy K, Smith J, Kolsum U, et al. COPD phenotype description using principal components analysis. Respir Res. 2009;10(1):41. doi:10.1186/1465-9921-10-41
- George L, Taylor AR, Esteve-Codina A, et al. Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy. 2020;75(2):370–380. doi:10.1111/all.14016
- Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC
- Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J. 2017;50(1):1700761.
- Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037–47.e10. doi:10.1016/j.jaci.2018.04.010
- Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC
- Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. doi:10.1016/S2213-2600(19)30190-0
- Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016;71(2):118–125. doi:10.1136/thoraxjnl-2015-207021
- Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X
- Global Initiative for Chronic Obstructive Lung Diseases. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2021 report). Available from: https://goldcopd.org/2021-gold-reports/. Accessed August 7, 2021.
- Christenson SA, Steiling K, van den Berge M, et al; Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758–766. doi:10.1164/rccm.201408-1458OC
- Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349. doi:10.2147/COPD.S152291
- Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5(9):747–759. doi:10.1016/S2213-2600(17)30217-5
- George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34–51. doi:10.1177/2040622315609251
- Singh D, Kolsum U, Brightling C, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.00162414
- Oshagbemi O, Franssen F, Braeken D, et al. Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. Pharmacoepidemiol Drug Saf. 2018;27(11):1191–1199. doi:10.1002/pds.4655
- Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1819–1824. doi:10.2147/COPD.S129787
- Kolsum U, Ravi A, Hitchen P, et al. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017;18(1):73. doi:10.1186/s12931-017-0559-0
- Oh Y, Lee K, Hong Y, et al. Blood eosinophil count as a prognostic biomarker in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3589–3596. doi:10.2147/COPD.S179734
- Wu H, Zhuo K, Cheng D. Prevalence and baseline clinical characteristics of eosinophilic chronic obstructive pulmonary disease: a meta-analysis and systematic review. Front Med. 2019;6:282. doi:10.3389/fmed.2019.00282
- Landis S, Suruki R, Maskell J, et al. Demographic and clinical characteristics of COPD patients at different blood eosinophil levels in the UK clinical practice research datalink. COPD. 2018;15(2):177–184. doi:10.1080/15412555.2018.1441275
- Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
- von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi:10.1016/S0140-6736(07)61602-X
- Van Ryswyk E, Anderson CS, Antic NA, et al. Predictors of long-term adherence to continuous positive airway pressure in patients with obstructive sleep apnea and cardiovascular disease. Sleep. 2019;42(10). doi:10.1093/sleep/zsz152
- Colonna AL, Griffiths TM, Robison DC, et al. Cholecystostomy: are we using it correctly? Am J Surg. 2019;217(6):1010–1015. doi:10.1016/j.amjsurg.2019.04.002
- Casanova C, Celli BR, De-torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50(5):1701162. doi:10.1183/13993003.01162-2017
- Shin SH, Park HY, Kang D, et al. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respir Res. 2018;19(1):134. doi:10.1186/s12931-018-0840-x
- DiSantostefano R, Hinds D, Le H, et al. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med. 2016;112:88–96. doi:10.1016/j.rmed.2016.01.013
- Harsløf M, Pedersen KM, Nordestgaard BG, et al. Low high-density lipoprotein cholesterol and high white blood cell counts: a Mendelian Randomization Study. Arterioscler Thromb Vasc Biol. 2021;41(2):976–987. doi:10.1161/ATVBAHA.120.314983
- Tucker B, Sawant S, McDonald H, et al. The association of serum lipid and lipoprotein levels with total and differential leukocyte counts: results of a cross-sectional and longitudinal analysis of the UK biobank. Atherosclerosis. 2021;319:1–9. doi:10.1016/j.atherosclerosis.2020.12.016
- Yvan-Charvet L, Pagler T, Gautier E, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689–1693. doi:10.1126/science.1189731
- Westerterp M, Gourion-Arsiquaud S, Murphy AJ, et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell. 2012;11(2):195–206. doi:10.1016/j.stem.2012.04.024
- Feng Y, Schouteden S, Geenens R, et al. Hematopoietic stem/progenitor cell proliferation and differentiation is differentially regulated by high-density and low-density lipoproteins in mice. PLoS One. 2012;7(11):e47286. doi:10.1371/journal.pone.0047286
- Markelić I, Hlapčić I, Rogić D, et al. Lipid profile and atherogenic indices in patients with stable chronic obstructive pulmonary disease. Nutr Metab Cardiovasc Dis. 2021;31(1):153–161. doi:10.1016/j.numecd.2020.07.039
- Reed RM, Iacono A, DeFilippis A, et al. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J Heart Lung Transplant. 2011;30(6):674–678. doi:10.1016/j.healun.2010.12.010
- Tisi GM, Conrique A, Barrett-Connor E, et al. Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). Metabolism. 1981;30(4):340–346. doi:10.1016/0026-0495(81)90113-X
- Wu Z, Yang D, Ge Z, et al. Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research. J Thorac Dis. 2018;10(8):340–346. doi:10.21037/jtd.2018.08.67
- Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019;394(10196):407–418. doi:10.1016/S0140-6736(19)31147-X